Potential advantages of PAS ports in pediatric patients with hemophilia and high titer inhibitors.

被引：0
|
作者：
Heisel, MA
Nelson, SC
Osip, JM
机构：
[1] UNIV MINNESOTA HOSP & CLIN,CTR COMPREHENS HEMOPHILIA,MINNEAPOLIS,MN
[2] CHILDRENS HLTH CARE,MINNEAPOLIS,MN
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3480 / 3480
页数：1
相关论文
共 50 条
  • [21] Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
    Tjonnfjord, Geir E.
    Holme, Pal Andre
    VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (04) : 527 - 531
  • [22] Predictors of response to combination therapy with recombinant Factor VIIa and Factor VIII in patients with hemophilia A and high titer inhibitors
    Dunn, Amy L.
    Nguyen, Brenda
    Baldwin, W. Hunter
    Kenet, Gili
    Meeks, Shannon L.
    HAEMOPHILIA, 2014, 20 : 42 - 42
  • [23] Randomized, prospective clinical trial of rFVIIa for secondary prophylaxis in hemophilia patients with inhibitors.
    Konkle, Barbara A.
    Ebbesen, Liselotte S.
    Friedrich, Ute
    Bianco, Raul P.
    Lissitchkov, Toshko
    Rusen, Luminita
    Serban, Margit A.
    BLOOD, 2006, 108 (11) : 230A - 230A
  • [24] Outcome measures for adult and pediatric hemophilia patients with inhibitors
    Hermans, Cedric
    Auerswald, Guenter
    Benson, Gary
    Dolan, Gerry
    Duffy, Anne
    Jimenez-Yuste, Victor
    Ljung, Rolf
    Morfini, Massimo
    Lambert, Thierry
    Osooli, Mehdi
    Salek, Silva Zupancic
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (02) : 103 - 111
  • [25] TREATMENT OF HEMOPHILIA WITH INHIBITORS: AN ADVANCE IN OPTIONS FOR PEDIATRIC PATIENTS
    McCarthy, Joan
    Mathew, Prasad
    JOURNAL OF EMERGENCY NURSING, 2011, 37 (05) : 474 - 476
  • [26] Plasma derived FVIII ITI outcomes in two children with hemophilia A and high titer inhibitors
    Alamelu, J.
    Phillott, A.
    HAEMOPHILIA, 2018, 24 : 86 - 87
  • [27] Successful major and minor surgery in patients with hemophilia and high titer inhibitor
    Balkan, C.
    Yilmaz, D.
    Kavakli, K.
    Aydogdu, S.
    Ozcan, C.
    Ay, Y.
    HAEMOPHILIA, 2010, 16 : 21 - 21
  • [28] Safe concurrent use of intravenous or oral tranexamic acid and aPCC in patients with hemophilia complicated by high-titer inhibitors
    Stefanska-Windyga, E.
    Baran, B.
    Czubak, G.
    Windyga, J.
    HAEMOPHILIA, 2012, 18 : 20 - 20
  • [29] Monitoring IgE and IgG subclasses in hemophilia B patients with factor IX (FIX) inhibitors.
    Leitermann, K
    Berntorp, E
    Ewenstein, BM
    Sommer, S
    Thompson, AR
    Rup, BJ
    BLOOD, 1997, 90 (10) : 145 - 145
  • [30] Assessment of quality of life in hemophilia patients with inhibitors. Development of an inhibitor-specific questionnaire
    von Mackensen, S.
    Riva, S.
    Khair, K.
    Yee, T. T.
    Rocino, A.
    Escuriola, C.
    Oldenburg, J.
    Gringeri, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 931 - 932
12345